ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1672547
This article is part of the Research TopicInnovative Therapeutic Approaches for Complex Cancers: Exploring New StrategiesView all 13 articles
Safety and Efficacy of laparoscopic radical gastrectomy after neoadjuvant chemotherapy plus immunotherapy:a retrospective cohort study
Provisionally accepted
- First Affiliated Hospital of Chongqing Medical University, Chongqing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
BACKGROUND: Gastric cancer (GC) is a highly prevalent type of malignant tumor worldwide. Patients with locally advanced gastric cancer (LAGC) frequently have a poor prognosis due to the inability to achieve R0 resection. Neoadjuvant chemotherapy (NAC) can enhance survival rates, although its effectiveness is limited. Immune checkpoint inhibitors (ICIs) have demonstrated potential in treating advanced gastric cancer, but their efficacy in neoadjuvant therapy (NAT) for LAGC remains unclear. The aim of this study was to evaluate the safety, pathological response and survival outcome of neoadjuvant chemotherapy plus immunotherapy (NACI) versus NAC alone after laparoscopic gastrectomy for GC. METHODS:A retrospective analysis of 375 patients with LAGC who received neoadjuvant therapy from 2015 to 2022 was performed. Patients were divided into NACI group (168 patients) and NAC group (207 patients) according to NAT regimen. RESULT:The rate of pathologic complete response (pCR, 20.2% vs. 12.6%, P=0.04) and the rate of major pathological response (MPR, 31.0% vs. 18.8%, P=0.007) in the NACI group are significantly higher than those in the NAC group, and the NACI group also had a higher rate of R0 resection (91.3% vs. 84.1%, P=0.028). The NACI group experienced a more significant decline in ypT0 (22.0% vs. 13.0%, P=0.022) and ypN0 (67.3% vs. 53.6%, P=007), but there was no difference in disease-free survival (DFS) and overall survival (OS) at 3 years between the two groups (P>0.05). CONCLUSION: NACI significantly improved pCR rates and R0 resection rates in patients with LAGC without increasing perioperative risk, but did not translate into short-term survival benefits.
Keywords: Neoadjuvant chemotherapy, Immunotherapy, Pathologic complete response, locallyadvanced gastric cancer, Laparoscopic radical gastrectomy
Received: 24 Jul 2025; Accepted: 25 Aug 2025.
Copyright: © 2025 Xiong, Zou, Zhang, He, Tang, Zhong and Qian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Kun Qian, First Affiliated Hospital of Chongqing Medical University, Chongqing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.